Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter

This article was originally published in The Pink Sheet Daily

Executive Summary

Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.

You may also be interested in...



New House FDA Appropriations Chair Aderholt An Unknown

Alabama Republican Robert Aderholt takes over as FDA appropriations subcommittee chair after running homeland security subcommittee; Mikulski to run Senate Appropriations Committee.

FDA Generic, Biosimilar User Fees Could Be Locked Up Under Short-Term Funding Bill

A continuing resolution does not specifically allow FDA to spend the fees, but the generic drug backlog and biosimilar product development fees are expected to be available.

GDUFA Guidance Offers Peek At Generic Drug User Fee Levels

A new guidance includes preliminary estimates of backlog, application and drug master file fees under the new generic drug user fee program. However, the agency must wait for Congress to pass an FY 2013 appropriations bill or continuing resolution with language allowing it to collect the new revenue.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS074318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel